Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
Go back to Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint| (NASDAQ: NVCR) | Delayed: 17.83 +0.12 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.71 | 52 Week High | $28.95 | |||
| Open | $17.62 | 52 Week Low | $5.95 | |||
| Day High | $18.05 | P/E | N/A | |||
| Day Low | $17.25 | EPS | $0.00 | |||
| Volume | 390,370 | |||||
| (NASDAQ: ZLAB) | Delayed: 17.36 -0.28 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.64 | 52 Week High | $ | |||
| Open | $17.26 | 52 Week Low | $ | |||
| Day High | $17.39 | P/E | N/A | |||
| Day Low | $16.97 | EPS | $ | |||
| Volume | 701,960 | |||||
